Lifeboat Foundation

An exciting new cancer drug has recently entered into a phase 1 clinical trial supported by promising pre-clinical work. The drug, named AOH1996, targets a protein called proliferating cell nuclear antigen (PCNA), an essential player in the biological processes of DNA replication and repair. A team of researchers from City of Hope published the data describing how they identified and characterized AOH1996 in Cell Chemical Biology last week. Since then, the news of AOH1996 has appeared prominently in both scientific and mainstream media.

Using a rational drug design approach that develops drugs based on their specific biological targets, the researchers identified AOH1996. Lead researcher Linda Malkas named the drug after Anna Oliva Healey, a girl born in 1996 who succumbed to neuroblastoma at age 9.

In the laboratory, the researchers tested AOH1996 on over 70 different kinds of tumor cells as well as some healthy control cells. While the drug killed the cancer cells, it notably does not affect non-cancer cells, including blood cells and the cells lining the airway. This indicates AOH1996 as a selective drug that will suppress tumor growth but likely not cause adverse effects that can occur when a cancer drug damages healthy cells.

Date August 25, 2023 August 28, 2023

Researchers demonstrated that the crosstalk between IL1RL1+ regulatory T-cells (Treg) and cancer-associated fibroblasts (CAFs) drives the tissue repairing.

Innovative technology that creates ultra-thin layers of human cells in tube-like structures could spur development of lifelike blood vessels and intestines in the lab.

The technique, known as RIFLE – rotational internal flow layer engineering – enables the construction of separate layers as delicate as one cell thick.

Such versatility is crucial to developing accurate human models of layered tubular tissue for use in research, offering an important alternative to animal models, experts say.

That’s why we were struck to see a team of scientists that includes researchers from the name-brand Harvard Medical School and Massachusetts Institute of Technology sounding off about what they say are promising new leads, published this month in the journal Aging.

“We identify six chemical cocktails, which, in less than a week and without compromising cellular identity, restore a youthful genome-wide transcript profile and reverse transcriptomic age,” reads the paper. “Thus, rejuvenation by age reversal can be achieved, not only by genetic, but also chemical means.”

Sounds big, right? The researchers claim they pinpointed six treatments that can reverse aging in cells and turn them into a more “youthful state,” according to a press release from Aging’s publisher, without causing dangerous unregulated cell growth.

Researchers led by Hiroshi Ohno at the RIKEN Center for Integrative Medical Sciences (IMS) in Japan have discovered a type of gut bacteria that might help improve insulin resistance, and thus protect against the development of obesity and type-2 diabetes. The study, published August 30 in the scientific journal Nature, involved genetic and metabolic analysis of human fecal microbiomes and then corroborating experiments in obese mice.

Insulin is a hormone released by the pancreas in response to blood sugar. Normally, it helps get the sugar into the muscles and liver so that they can use the energy. When someone develops insulin resistance, it means that insulin is prevented from doing its job, and as a result, more sugar stays in their blood and their pancreas continues to make more insulin. Insulin resistance can lead to obesity, pre-diabetes, and full-blown type-2 diabetes.

Our guts contain trillions of bacteria, many of which break down the carbohydrates that we eat when they would otherwise remain undigested. While many have proposed that this phenomenon is related to obesity and pre-diabetes, the facts remain unclear because there are so many different bacteria and there is a lack of metabolic data. Ohno and his team at RIKEN IMS have addressed this lack with their comprehensive study, and in the process, discovered a type of bacteria that might help reduce insulin resistance.

In a recent study, Ji Won Seo and team found the outcomes of single-incision laparoscopic surgery (SILS) better than conventional laparoscopic surgery (CLS) for treating gastric gastrointestinal stromal tumors (GISTs). The findings of the study were published in BMC Surgery.

Between November 2020 and April 2022, a group of 15 consecutive patients with gastric GIST underwent single-incision gastric wedge resection, forming the SILS group. This group’s early perioperative outcomes were then meticulously analyzed and compared with a corresponding group of 15 patients who had undergone conventional laparoscopic surgery (CLS). The selection criteria for the surgical approach were consistent with those used for traditional laparoscopic procedures for gastric GIST.

The study’s findings revealed several significant insights. The estimated blood loss and intraoperative blood transfusion were comparable between the SILS and CLS groups, signifying similar surgical efficacy and safety. Notably, the SILS group experienced no intraoperative complications or instances requiring a shift to multiple-port or open surgery.

A massive study of medical and genetic data shows that people with a particular version of a gene involved in immune response had a lower risk of Alzheimer’s and Parkinson’s disease.

Specific changes in our DNA that increase the risk of developing epilepsy have been discovered, in the largest genetic study of its kind for epilepsy coordinated by the International League Against Epilepsy, which includes scientists from the University of Melbourne and WEHI (Walter and Eliza Hall Institute of Medical Research).

Published today in Nature Genetics, this research advances our understanding of why epilepsy develops and could inform the development of new epilepsy treatments. The research was produced by the International League Against Epilepsy (ILAE) Consortium on Complex Epilepsies.

Epilepsy is a common brain disorder estimated to effect more than 50 million people worldwide, where nerve cell activity in the brain is disturbed, causing seizures. It has a genetic component that sometimes runs in families. In this study, researchers compared the DNA from almost 30,000 people with epilepsy to the DNA of 52,500 people without epilepsy from around the world. The differences between the two groups highlighted areas of DNA that may be involved in the development of epilepsy.